How long can you store retatrutide? Here's the honest answer

Last updated 2026-07-25

Why isn't there an official answer to how long you can store retatrutide?

Because retatrutide has never been approved by the FDA for any use. A search of Drugs@FDA, the agency's own database of approved drug products, returns no approved application for the generic name retatrutide ^[1]. No approval means no FDA-reviewed label, and no FDA-reviewed label means no official storage or stability section exists anywhere, for any formulation, at any concentration. Every approved injectable drug you've ever used, insulin, Ozempic, Mounjaro, comes with a label section that spells out refrigeration requirements, room-temperature windows, and in-use expiration after first puncture. That data comes from stability studies the manufacturer ran specifically to support the approved application. Retatrutide has no approved application, so it has no such studies in the public record. Anything you read about storage duration for a vendor-sold vial is not FDA-verified data. It's either a manufacturer's internal assumption, a guess extrapolated from similar peptides, or marketing copy.

What do the actual retatrutide trials say about handling the drug?

The registered trials tell us how retatrutide was dosed, not how long a home-stored vial stays potent. The phase 2 obesity trial, registered as NCT04881760 (A Study of LY3437943 in Participants Who Have Obesity or Are Overweight), used weekly subcutaneous injection across several dose arms including 12 mg, and ran through 48 weeks ^[2]. That study, published in the New England Journal of Medicine, reported a mean weight reduction of 24.2 percent at the 12 mg dose at 48 weeks against 2.1 percent for placebo ^[3]. Retatrutide has since moved into later-phase trials as well, including NCT05929066 ^[4] and NCT05882045 ^[5], and it has also been studied in registered type 2 diabetes trials beyond the obesity program ^[2]. All of that tells you dosing schedules and study design. None of it is a consumer-facing stability report. Clinical trial drug supply is manufactured under strict pharmaceutical GMP conditions, shipped in cold chain, stored by site pharmacists under controlled logs, and used within tightly defined windows dictated by the sponsor's internal stability data, data that is not published for the public to read. A vial sitting in someone's home fridge, purchased off a website, has nothing in common with that supply chain.

Is retatrutide legal to buy and store for personal use in the US?

No, and this matters more than any storage question. Under 21 U.S.C. 355, a new drug cannot be introduced into interstate commerce without an FDA-approved application ^[6]. Retatrutide has no approved application, so any sale or shipment of it into or within the US as a drug product violates that statute. Retatrutide also has no lawful compounding pathway. Section 503A allows a compounding pharmacy to use a bulk substance only if it meets an applicable USP or NF monograph, or, absent a monograph, if it's a component of an FDA-approved drug, or, absent both, if it appears on the 503A Bulks List ^[7]. Retatrutide fails all three tests. The final 503A Bulks List contains exactly six substances (Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide) and none of them is a peptide ^[8]. The separate 503B bulks list, governing outsourcing facilities, also excludes it ^[9]. FDA's own nominations tracking page confirms retatrutide isn't sitting in any interim category either ^[10]. It has never even been nominated. When FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to weigh seven peptides for the bulks list, BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, and epitalon, retatrutide wasn't among them ^[11]. And even a favorable vote wouldn't create a pathway on its own: advisory committee recommendations are non-binding, and adding anything to the list requires full notice-and-comment rulemaking ^[11]. 503A additionally requires that any bulk substance come from an establishment registered under FD&C Act section 510 and ship with a valid certificate of analysis ^[7]. Research-use-only material from an unregistered supplier fails this requirement regardless of anything else about the product. That's the gray-market retatrutide vial in a nutshell: it fails the ingredient test and it fails the sourcing test.

Does a 'research use only' label make storing or using it legal?

No. FDA has been direct about this. Intended use is judged by labeling claims, advertising, and statements made by the seller, not by a disclaimer buried in fine print ^[12]. If a site sells retatrutide alongside language about weight loss, dosing schedules, or fat metabolism, that marketing establishes the product as an unapproved drug for human use regardless of any 'not for human consumption' sticker on the vial. FDA made this explicit in a March 2026 warning letter to a peptide seller, writing that despite research-use-only labeling, the evidence from the company's website established that its products were intended to be drugs for human use, and the letter specifically named retatrutide as one of the products marketed on that site ^[1]. So a research-use disclaimer doesn't just fail to help you here. It's the exact fact pattern FDA has already flagged. If you're weighing a purchase because you saw 'retatrutide peptide buy' somewhere and want to know if it's above-board, this is your answer: the disclaimer is not doing what the seller wants you to believe it's doing.

How long does peptide stability typically last, in general terms?

Peptides as a drug class are chemically fragile compared to small-molecule drugs. Most approved peptide therapeutics, semaglutide and tirzepatide among them, are formulated as sterile solutions that require refrigeration before first use and have a defined, much shorter room-temperature window after the pen or vial is punctured. That's standard pharmaceutical chemistry: peptide bonds are vulnerable to hydrolysis, oxidation, and aggregation, and temperature, light, and agitation all accelerate degradation. But none of that translates into a specific number of days or weeks for retatrutide, because no approved retatrutide product exists to generate that label data. Extrapolating from semaglutide or tirzepatide storage windows to guess at retatrutide's stability is exactly that: a guess, not a fact. Anyone who tells you an unregulated vial is 'good for X months in the fridge' is making an unverified claim, whether they're a vendor or a forum poster.

Why can't a compounding pharmacy just make and store retatrutide legally?

Because the cascade in section 503A blocks it at every step, as covered above ^[7]. A compounding pharmacy can't legally reconstitute retatrutide the way it might legally reconstitute an FDA-approved sterile injectable, because retatrutide isn't an FDA-approved drug component, doesn't have a USP or NF monograph, and isn't on the Bulks List ^[8]. There's no lawful shelf for a pharmacist to store it on in the first place. This is worth separating from the how to reconstitute retatrutide question people ask when they've already acquired a vial. Reconstitution technique doesn't change legality. A perfectly executed reconstitution of an unlawfully sourced substance is still an unlawfully sourced substance.

How long does retatrutide diarrhea last, and does storage affect side effects?

In the phase 2 trial, gastrointestinal side effects including diarrhea, nausea, and vomiting were the most commonly reported adverse events, consistent with what's seen across the GIP/GLP-1/glucagon receptor agonist class ^[3]. The published trial data doesn't report a specific mean duration for diarrhea as an isolated symptom; GI effects in this drug class are generally described as mild-to-moderate, dose-related, and more common during dose escalation, easing somewhat as the body adjusts over subsequent weeks. For a full breakdown of what the trial reported by dose arm, see retatrutide side effects. On the storage question specifically: a degraded or improperly stored peptide product, one that's been through freeze-thaw cycles, left at room temperature too long, or contaminated during handling, could plausibly worsen GI tolerability or introduce contamination risks that have nothing to do with the drug's real profile. But there's no published data quantifying that for retatrutide, because there's no legal retail supply chain to study. This is one more reason unregulated vials are a bad bet: you can't separate 'normal drug side effect' from 'this vial degraded' when nobody verified what was in it or how it was kept.

What actually happens if you store an unregulated peptide vial in your fridge?

Nobody outside the manufacturer knows for certain, and that's the honest answer. Without FDA review, there's no public stability study telling you the real degradation curve for a specific research-use vial at a specific concentration and pH, stored at a specific temperature. Reputable pharmaceutical companies run months of accelerated and real-time stability testing before they'll put a number on a label. Gray-market sellers have no obligation to do any of that, and if they do, there's no regulator checking their work. What we can say: peptides generally degrade faster with heat exposure, light exposure, and repeated freeze-thaw cycling. A vial that's shipped without proper cold chain, sat in a warm mailbox for two days, then gone into a home fridge, has already had an uncontrolled window that no consumer can assess. That uncertainty stacks directly on top of the legal problem. You're more than taking on legal risk; you're taking on a product identity and stability risk that no lab has verified for you.

What are the lawful alternatives available right now?

Three incretin-based drugs are FDA-approved today and carry real labeling, real stability data, and real prescribing information. Semaglutide is approved and marketed as Ozempic and Wegovy. Tirzepatide is approved as Mounjaro and Zepbound ^[13]. And orforglipron, an oral GLP-1 receptor agonist, was approved as Foundayo under NDA 220934 in six strengths ranging from 0.8 mg to 17.2 mg, giving an approved oral incretin option to patients who might otherwise be tempted by investigational compounds ^[14]. All three have published storage and handling instructions on their FDA-reviewed labels, because that's what approval requires. None of them leave you guessing about shelf life or wondering whether a vial got too warm in transit. If you're comparing retatrutide's trial results to what's actually prescribable today, retatrutide peptide walks through the mechanism differences (retatrutide is a triple GIP/GLP-1/glucagon agonist, versus semaglutide's GLP-1-only action and tirzepatide's dual GIP/GLP-1 action) ^[3], and retatrutide dosage chart covers what dose arms were tested in trials, clearly labeled as trial data rather than a prescribing guide.

What should someone do if they already have an unregulated retatrutide vial?

Talk to a licensed clinician about what you actually took and when, especially if you develop symptoms. A doctor doesn't need you to have acted lawfully to treat you; they need accurate information. Don't guess your own storage duration or potency based on forum posts or seller claims, and don't try to extend use of a vial past whatever the seller claimed, since that claim was never independently verified in the first place. The more useful conversation, going forward, is with a clinician about lawful options. NIDDK publishes federal, non-commercial guidance on evidence-based weight management approaches that doesn't depend on any single drug being available ^[15], and that's a reasonable neutral starting point if you're trying to figure out what's actually backed by data versus what's being sold to you.

Can you legally import retatrutide from another country for personal use?

FDA has a published personal importation policy, and it does not create a right to import unapproved drugs; it describes narrow, discretionary circumstances under which FDA may decline to act against a personal shipment of an unapproved product, generally involving serious conditions with no US-approved treatment and no promotion targeting US consumers . Retatrutide doesn't fit that framework, since FDA-approved incretin drugs already exist for weight management and diabetes, meaning the 'no US treatment available' rationale doesn't apply the way it might for a truly orphan condition. Ordering retatrutide from an overseas peptide seller isn't a lawful workaround; it's importing an unapproved new drug in violation of 21 U.S.C. 355 ^[6], with the added complication that you have zero visibility into how the product was manufactured, shipped, or stored before it reached you.

Frequently asked questions

How long can you store retatrutide once reconstituted?

There's no FDA-reviewed answer, because retatrutide has no approved label or public stability data ^[1]. Vendor claims about post-reconstitution shelf life are unverified. Approved peptide drugs in the same broad class typically specify a short refrigerated window after mixing, but extrapolating that number to retatrutide is a guess, not a fact.

Does retatrutide need to be refrigerated?

No official guidance exists because there's no approved retatrutide product with FDA-reviewed storage instructions ^[1]. Peptides generally degrade faster at room temperature and with light exposure, so cold storage is the safer general assumption, but no verified time-and-temperature data exists for retatrutide specifically.

How long does retatrutide diarrhea last after a dose?

The phase 2 trial reported gastrointestinal effects, including diarrhea, as among the most common adverse events, generally more pronounced during dose escalation ^[3]. The trial publication doesn't isolate a specific mean duration for diarrhea alone; GI symptoms in this drug class are typically described as easing with continued dosing over subsequent weeks.

Is retatrutide legal to buy in the United States?

No. Retatrutide has no FDA approval ^[1], appears on no 503A or 503B bulks list ^[8][9], and any sale as a drug product violates 21 U.S.C. 355's requirement that new drugs have an approved application before entering commerce ^[6]. Vendor 'research use only' disclaimers don't change this ^[13].

Can a compounding pharmacy legally make retatrutide?

No. Section 503A requires a bulk substance to meet a USP/NF monograph, be a component of an approved drug, or appear on the 503A Bulks List ^[7]. Retatrutide meets none of those conditions, and the finalized Bulks List contains only six non-peptide substances ^[8].

Does a 'not for human consumption' label make a retatrutide vial legal to sell?

No. FDA judges intended use by labeling claims, advertising, and seller statements, not disclaimers ^[13]. A March 2026 warning letter cited a seller's own website language, despite a research-use disclaimer, as establishing that its retatrutide products were intended as drugs for human use ^[14].

What did the retatrutide phase 2 trial actually measure?

NCT04881760 tested weekly subcutaneous retatrutide across dose arms in people with obesity or overweight ^[2]. At 48 weeks, the 12 mg dose produced a mean 24.2 percent weight reduction versus 2.1 percent for placebo, published in the New England Journal of Medicine ^[3].

Is retatrutide on the FDA's list of substances allowed for compounding?

No. FDA's public tracking page for bulk drug substances nominated under section 503A does not list retatrutide in any category ^[10], and it has never even been nominated for the list, unlike the seven peptides FDA's advisory committee reviewed in July 2026 ^[11].

What's the difference between retatrutide and approved drugs like Zepbound or Wegovy?

Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors, while semaglutide (Ozempic/Wegovy) acts only on GLP-1 and tirzepatide (Mounjaro/Zepbound) acts on GIP and GLP-1 ^[3]. Only semaglutide and tirzepatide are FDA-approved ^[15]; retatrutide remains investigational with no approved label or storage data ^[1].

Can I import retatrutide legally for personal use from overseas?

FDA's personal importation policy allows narrow discretionary exceptions, generally for serious conditions with no approved US treatment ^[18]. That doesn't apply to retatrutide, since approved incretin drugs already exist for obesity and diabetes ^[15][16]. Importing it is bringing an unapproved new drug into the US, which conflicts with 21 U.S.C. 355 ^[6].

Is there an oral alternative to retatrutide that's actually approved?

Yes. Orforglipron, an oral GLP-1 receptor agonist, was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg ^[16]. It's not a triple agonist like retatrutide, but it is a lawful, prescribable option with FDA-reviewed labeling and storage guidance.

Why doesn't a favorable advisory committee vote mean retatrutide could soon be compounded?

Because advisory committee recommendations are non-binding, and adding any substance to the 503A Bulks List requires full notice-and-comment rulemaking, more than a vote ^[11]. Retatrutide wasn't even among the seven peptides reviewed at the July 2026 meeting, so it isn't currently in that process at all.

Sources

1. Drugs@FDA, FDA-approved drug products database: A search for the generic name retatrutide returns no FDA-approved product, meaning no official label or stability data exists.
2. ClinicalTrials.gov, NCT04881760: Registration record for the phase 2 retatrutide obesity trial, dose arms, weekly subcutaneous route, and that retatrutide has also been studied in type 2 diabetes trials.
3. Jastreboff AM et al., New England Journal of Medicine, 2023: Reported 24.2 percent mean weight reduction at 12 mg versus 2.1 percent placebo at 48 weeks; GI adverse events; retatrutide's triple GIP/GLP-1/glucagon receptor mechanism.
4. ClinicalTrials.gov, NCT05929066: Registration record of a later-phase retatrutide trial listing enrollment criteria, comparators, and endpoints.
5. ClinicalTrials.gov, NCT05882045: Second later-phase retatrutide trial registration providing an independent record of dosing and design.
6. 21 U.S.C. 355: A new drug cannot be introduced into interstate commerce without an FDA-approved application, the statutory basis for retatrutide's unavailability outside trials.
7. 21 U.S.C. 353a(b)(1)(A)(i): Section 503A's cascade requires a USP/NF monograph, or component of an approved drug, or Bulks List presence before compounding is permitted; retatrutide meets none.
8. 21 CFR 216.23, eCFR: The final 503A Bulks List contains exactly six non-peptide substances and does not include retatrutide.
9. 21 CFR 216.24, eCFR: The separate 503B bulks list for outsourcing facilities also does not include retatrutide.
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's public tracking list of nominated bulk drug substances for 503A compounding does not include retatrutide.
11. Federal Register, Docket FDA-2025-N-6895: FDA's Pharmacy Compounding Advisory Committee reviewed seven other peptides in July 2026, not retatrutide, and advisory votes don't create a compounding pathway without rulemaking.
12. 21 CFR 201.128: Intended use is established by labeling claims, advertising, and seller statements, not by disclaimers.
13. Drugs@FDA, NDA 220934: Orforglipron was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg.
14. NIDDK, Weight Management: NIDDK publishes federal, evidence-based guidance on weight management as a neutral reference point.
15. FDA, Personal Importation: FDA's personal importation policy describes narrow discretionary circumstances and does not create a right to import unapproved drugs like retatrutide.